Chimeric antigen receptor (CAR) T cells targeting the CD19 antigen are effective in treating adults and children with B-cell malignancies. Place-of-care manufacturing may improve performance and accessibility by obviating the need to cryopreserve and transport cells to centralized facilities. Here we develop an anti-CD19 CAR (CAR19) comprised of the 4-1BB co-stimulatory and TNFRSF19 transmembrane domains, showing anti-tumor efficacy in an in vivo xenograft lymphoma model. CAR19 T cells are manufactured under current good manufacturing practices (cGMP) at two disparate clinical sites, Moscow (Russia) and Cleveland (USA). The CAR19 T-cells is used to treat patients with relapsed/refractory pediatric B-cell Acute Lymphocytic Leukemia (ALL; n = 31) or adult B-cell Lymphoma (NHL; n = 23) in two independently conducted phase I clinical trials with safety as the primary outcome (NCT03467256 and NCT03434769, respectively). Probability of measurable residual disease-negative remission was also a primary outcome in the ALL study. Secondary outcomes include complete remission (CR) rates, overall survival and median duration of response. CR rates are 89% (ALL) and 73% (NHL). After a median follow-up of 17 months, one-year survival rate of ALL complete responders is 79.2% (95%CI 64.5‒97.2%) and median duration of response is 10.2 months. For NHL complete responders one-year survival is 92.9%, and median duration of response has not been reached. Place-of-care manufacturing produces consistent CAR-T cell products at multiple sites that are effective for the treatment of patients with B-cell malignancies.
Pediatric B-acute lymphoblastic leukemia (B-ALL) is highly curable, but 2–3% of patients have refractory disease and 10–15% will relapse after chemotherapy1,2,3,4. Non-Hodgkin’s lymphoma (NHL) is often successfully treated with combination chemoimmunotherapy5,6,7. However, patients who are resistant to initial chemotherapy have a poor prognosis8. CD19 is a 95 kDa glycoprotein present on the B-cell surface that is expressed by most B-cell malignancies including NHL and ALL9,10. CD19-targeting immunotherapies such asbispecific antibodies and CAR T cells have induced remission in children and adults with relapsed/refractory B-ALL and NHL11,12,13,14,15,16,17,18.
The remissions in pediatric B-ALL and adult diffuse large B cell lymphoma (DLCL) led to FDA authorization for KymriahTM (tisagenlecleucel, Novartis) and YescartaTM (axicabtageneciloleucel, Gilead)12,19,20. However, in a phase 2 study of tisagenlecleucel in pediatric and young adult patients with CD19 + ALL, 7.6% of patients did not receive treatment due to manufacturing failures12. Additionally, in a study using the same CAR construct in adults with lymphoma, 13.2% of patients did not receive treatment due to manufacturing failure, which has been reported in 3–13% of commercially manufactured products19. Another significant proportion of patients were not treated due to disease progression12. These studies suggest that alternative modalities to centralized manufacturing are needed.
Here, we report the development of a CD19-targeting CAR comprised of the TNF receptor superfamily member 19 (TNFRSF19) transmembrane domain, termed CAR19. CAR19 demonstrates robust expression in primary human T cells and shows potent target-specific cytotoxicity and cytokine response in vitro and is effective in rejecting CD19+ tumors in an in vivo xenograft NSG lymphoma model. Furthermore, robust clinical responses are observed in patients with relapsed/refractory B cell malignancies treated with place-of-care manufactured CAR19-T cells in two different locations. Place-of-care manufacturing is defined as near the point of patient treatment allowing cell products to be produced and infused without the need for cryopreservation. The results of this study support the safety and efficacy of this approach.
Design of the chimeric antigen receptor targeting CD19
To identify new T cell functionality associated with alterations in structural and transmembrane sequence we carried homology searches, restricted to human proteins, to identify cell surface glycoproteins analogous to CD8 transmembrane domain amino acid sequence (BLAST®, NCBI, NIH)21. Homology search results were annotated to reflect known lymphocyte cell surface proteins, and although sequence diversity was greater than anticipated, motifs in common (highlighted in Supplementary Fig. 1) could be identified in TNFRSF9 (CD137), TNFRSF16 (CD271, NGFR, or commonly LNGFR), and TNFRSF19 (TROY). Transmembrane domains used were as predicted by TMHMM 2.0 (Prediction of transmembrane helices in proteins, DTU Health Tech, Denmark). Each of these transmembrane domains were linked at C-terminus of the spacer domains, which joined them to the FMC63 CD19-binder. CD8 linker joined to CD8TM, CD4TM, TNFRSF19, TNFRSF16, and TNFRSF9 were then tested for surface expression and killing of CD19+ leukemia cell lines. Also tested were sequence length equivalent TNFRSF16, TNFRSF9, and TNFRSF19 linker domains, linked to their native transmembrane (TM) domain. Of note, TNFRSH16 gave the highest cell surface expression as determined by flow cytometry analysis, but was not functional in cytotoxicity assays, and did not control Raji cell growth in an NSG mouse model. Only CD8 linker combined with TM-TNFRSF19 showed equivalent or better activity compared to constructs encoding CD8 linker and TM domains in either in vitro or NSG mouse models of anti-leukemic activity22.
CAR19 was therefore constructed by combining CD19-targeting single chain fragment variable (ScFv) sequence FMC63 in frame with CD8 hinge sequence, a transmembrane region sequence from TNFRSF19, a co-stimulatory domain derived from 4-1BB/CD137, and a CD3ζ activation domain (Fig. 1A). All sequences except for the FMC63 scFv, which was derived from heavy and light chains of a murine antibody, are of human origin. We compared CAR19 to its predecessor, which comprised the same sequences except the TNFRSF19 transmembrane domain was substituted for the CD8 transmembrane domain (CAR19.8; Fig. 1A).
CAR-T cells expressing variant CAR19 have similar anti-leukemic effects
Having confirmed the expression of CAR19 in primary human T cells, we next evaluated its anti-leukemic effects on CD19+ cancer cell lines Raji (NHL), Reh (ALL), or with CD19‒ control lines K562 or 293T (Fig. 1C–F, respectively). Target cell lines were stably transduced to express firefly luciferase, thus enabling assessment of target cell killing by luminometry. CAR-T cell killing of target cells at three effector to target ratios (E:T) of 5:1, 10:1, and 20:1 were analyzed. In CD19+ target lines, Raji and Reh, CAR19 and CAR19.8 both demonstrated effective, E:T ratio-dependent target killing. By contrast, UTD control had no killing capacity against Raji or Reh, underscoring that the killing was indeed CAR-dependent (Fig. 1C–F). By contrast, when CAR-T cells were incubated with CD19-negative target lines K562 and 293T, no target killing occurred in either CAR19 or CAR19.8 groups. Therefore, the cytotoxic function of CAR19 and CAR19.8 in vitro was target-dependent (Fig. 1C–F).
Next, we examined the capacity of CAR-T cells to produce cytokines after exposure to target cells. Co-culture media supernatants were harvested following overnight incubation of CAR-T cells with Raji cell targets at E:T ratio of 10:1 and analyzed by ELISA for T cell inflammatory and homeostatic cytokines crucial for CAR-T cell function: IL-2, IFNγ, and TNFα (Fig. 1G–I, respectively). T cells transduced with lentiviral vector to express GFP, and UTD, were included as negative controls. In addition, CAR-T cell alone control, consisting of CAR-T cells incubated under same conditions as co-incubated groups, but in the absence of target cells, was utilized (Fig. 1I). CAR19 and CAR19.8 yielded robust, statistically significant increases in the levels of IL-2, IFNγ, and TNFα in culture media after co-incubation with the CD19+ Raji target cells, whereas cytokine levels in the negative control groups UTD and GFP remained at baseline. A small but statistically significant increase in the production of IL-2 and TNF-alpha by CAR19 was noted (Fig. 1G–I). Importantly, in CAR-T cell alone test groups, no increases in the levels of IL-2, IFNγ, or TNFα were observed, indicating that cytokine induction requires the presence of Raji cell targets, and there was no evidence of tonic CAR-T cell signaling (Fig. 1G–I).
CAR T cells expressing variant CAR19 molecules control Raji lymphoma tumors in NSG xenograft model
Having established the in vitro functionality of the variant CAR19-T cells, we proceeded to examine their potential efficacy in vivo. NSG mice were implanted with Raji-luc lymphoma on study day 0. Seven days after tumor implant, five million of previously cryopreserved CAR19 or CAR19.8-T cells were administered to each mouse. Tumor progression was monitored by bioluminescent IVIS imaging with tumor alone (TA) and cells transduced with GFP-expressing lentiviral vector (GFP) serving as negative controls (Fig. 2A). Both CAR19 and CAR19.8-T cell groups were able to control tumor burden throughout the study (Fig. 2B).
Fresh CAR19-T cells reduce tumor burden faster in vivo in NSG mice than cryopreserved CAR19-T cells
Having determined the anti-tumor potency of the designedCAR19-T cells in vivo, we evaluated whether freshly prepared vs. cryopreserved CAR19-T cells impacts the rate or the magnitude of tumor regression in vivo (Fig. 2C). CAR19 T cells, with highly similar transduction efficiencies and CD4:CD8 ratios were either administered fresh, or frozen and thawed prior to administration to animals. Administration of fresh CAR19 T cells yielded significantly lower tumor burden as compared to dose-matched frozen CAR19 T cells on study days 11 and 13 (p < 0.005, t test). On study days 21 and 28, tumors were similarly and potently rejected by both fresh and frozen cell-treated groups. However, fresh cells reduced the tumor burden sooner by 8 days, and immediately started reducing the tumor burden, while frozen CAR19-T cells first permitted tumor growth before controlling growth (Fig. 2C).
Place-of-care manufacturing of CAR19-T cells has a low cell production failure rate
1 × 108 CD3+ lymphocytes were collected successfully by leukapheresis from all enrolled patients and loaded into the CliniMACS Prodigy®. Manufacturing success rate was 96% (n = 30) and 100% in the Moscow and Cleveland cohort, respectively (Supplementary Fig. 2A, B). Except for two patients in Cleveland, all CAR19 cells were infused fresh. CAR19 from both cohorts had similar cellular composition with over 90% CD3+ cells. The pediatric cohort had similar CD4:CD8 ratio while the NHL cohort had a higher but not statistically significant CD4:CD8 T cell ratio (Supplementary Fig. 2A). Seven patients in the NHL cohort were manufactured in 8 days.
Median transduction rate was 60% and 48%, respectively, in Moscow and Cleveland (Supplementary Fig. 2B). The median apheresis to infusion time was 13 days in both cohorts (Supplementary Fig. 2A, B). After infusion, CAR19-T levels peaked between days 14–21 (Supplementary Fig. 2C, D) and were not influenced by cell dose (which did not influence CAR19 persistence).
CAR19-T cells demonstrate robust anti-tumor activity in ALL and NHL patients
The ALL trial enrolled heavily pre-treated and refractory patients (n = 31); 42% had failed an allogeneic transplant (Table 1). In parallel, 23 relapsed/refractory adult lymphoma patients were treated. All patients and/or legal guardians provided informed consent. Twenty-seven ALL patients were evaluable for day 28 response (Fig. 3A). Among them, MRD-negative CR rate was 89% (n = 24). CR rate in the intent-to-treat population was 77%. In addition, all patients that did not survive for day-28 response evaluation had no evidence of leukemia on day 14 after cell infusion. Characteristics of non-responders are presented in Supplementary Table 1. Leukemia load, previous transplant or blinatumomab exposure, or LDH levels did not predict response. Allogeneic hematopoietic transplant was not used routinely as consolidation therapy. At a median follow-up of 17 months, 16 patients relapsed (CD19 negative in 8). Median time to relapse was 264 days (range, 89–696). One-year overall survival (OS) estimate (intention to treat) for the ALL cohort is 67.7% (95% CI 53.1–86.4%). For ALL patients achieving CR at day 28 (n = 24), one-year OS and PFS estimates are 79.2% (95% CI 64.5–97.2%) and 37.5% (95% CI 22.4–62.9%). Median duration of response for patients in CR was 310 days (10.2 months; 95% CI 8.2 months—not reached). Three patients received allogeneic hematopoietic transplant after achieving CR. All acute leukemia patients achieving CR (n = 24) had B cell aplasia on day 30. The proportion of patients in continued remission with persistent B cell aplasia (a secondary study endpoint) decreased over time (Supplementary Fig. 2E). One year after infusion, 67% of evaluable patients had CAR-T cell persistence (Supplementary Fig. 2D).
NHL patients received a median number of five prior therapies (range, 2–7; Table 1); nine subjects had the primary refractory disease and 18 had disease refractory to the last treatment regimen. One subject died on day 8 after CAR19 infusion as a result of CRS associated with a high tumor burden (Fig. 3B). Among the 22 evaluable subjects, 16 patients achieved CR and two, partial response (PR). For the intention to treat the population (n = 23), the CR rate was 70%, and the overall response rate, 83%. Three patients did not respond, two of whom died of progressive disease, 72 and 228 days after treatment (Supplementary Table 2). Univariate analysis did not reveal predictors of response, disease status, lymphoma subtype, previous transplant, or LDH levels. Likely due to the small number of non-responders, univariate analyses did not reveal statistically significant predictors of response, including disease status, lymphoma subtype, previous autologous transplant, or baseline LDH, ferritin, and CRP levels (Supplementary Table 3).
After a median follow-up of 17 months (range 0–26), 6 patients have died, with a 1-year OS estimate (intention to treat) of 77.7% (95% CI 62.3–97.1%). Three CR patients have relapsed. All were asymptomatic, CD19+ and detected on surveillance imaging performed at 6 months follow-up. One subject who achieved day 30 partial imaging metabolic response progressed on day 60 imaging, with CD19-disease. One-year OS and PFS estimates for CR patients were 92.9% (95% CI 80.3–100%) and 81.2% (95% CI 64.2–100%), respectively (Fig. 4C–J). The median duration of response has not been reached (95% CI NR–NR).
Prophylactic tocilizumab, 8 mg/kg intravenously 1 h prior to CAR-T cell infusion on day 0, was administered to all pediatric patients. Five patients were treated at dose level 1 (0.5 × 106/kg), then 2 DLTs were seen, then five patients were treated at dose level 0 (0.1 × 106/kg), five additional patients at dose level 1, 10 patients at dose level 2 (1 × 106/kg), and three patients at dose level 3 (3 × 106/kg), then 1 case of DLT was seen, detailed in Supplementary Fig. 3A.
Overall,19 (63%) patients had either CRS or ICANS, in 13 (68% of all CRS/ICANS) cases severity was grade 1–2. Severe (grade 3–5) adverse events occurred in six (20%) patients (Supplementary Tables 4 and 5). There were two (7%) cases of severe CRS (grade 3 n = 1, grade 4 n = 1), four (13%) cases of severe ICANS (grade 3 n = 2, grade 5 n = 2). Additionally, two cases of probable graft-versus-host disease (GVHD) reactivation and 4 cases of culture-positive sepsis were recorded. Overall, seven (23%) patients were admitted to the ICU due to CRS (n = 1), sepsis (n = 2) or ICANS (n = 4). The median time to first signs of CRS or ICANS was 7 (range, 1–17) days. Eighteen patients received dexamethasone, the median number of 2 doses, and 13 patients received additional tocilizumab at a median of 1 dose.
Two patients developed fatal brain edema. The first presented on day 8 after 0.5 × 106/kg CAR19 in a patient with high leukemia burden and was associated with autopsy-documented multi-drug resistant Klebsiella pneumonia encephalitis. The second case was diagnosed on day 4 after 3 × 106/kg CAR19 infusion in a patient with high leukemia burden.
Overall, 13 patients died during follow-up, 10 of them after ALL progression or relapse. Three patients died due to CRS + sepsis (n = 1), ICANS + sepsis (n = 1) or ICANS (n = 1) before day 28 response assessment. Overall, non-relapse mortality was 10% (3 of 31 patients) in the ALL cohort.
None of the patients with <20% bone marrow blasts developed grade 3–5 CRS/ICANS vs. seven (54%) among subgroup with >20% blasts (p = 0.002; Supplementary Table 4). There was also a significant correlation between severe CRS and ICANS with LDH levels (Supplementary Fig. 4).
Prophylactic tocilizumab was instituted in the NHL trial after May 2019, informed by the Russian trial, administered at a dose of 8 mg/kg, 1 h prior to CAR-T cell infusion.
Three patients were initially treated at dose level 1 (0.5 × 106 CAR T cells/kg) without dose-limiting toxicities; one patient treated in dose level 2 (1 × 106 CAR T cells/kg) had lethal CRS, resulting in expansion of that dose level to a total of six patients initially. This dose level was expanded further to an additional 10 patients after CAR T manufacturing was shortened from 12 to 8 days. No additional dose-limiting toxicities were observed at this dose level or at the target dose of 2 × 106 CAR T cells/kg (Supplementary Fig. 3B). During the expansion phase of dose level 2, one subject with high tumor burden and elevated baseline inflammatory markers was administered a reduced dose of 0.5 × 106 cells/kg.
Adverse events included CRS in 12 patients (Supplementary Table 4). The median time to CRS was 4 days (range, 1–7). CRS was graded 1–2 (n = 11), while one patient died of severe CRS in the context of bulky disease after 1 × 106/kg CAR19 cells. Nine patients required tocilizumab for the treatment of grade ≥2 CRS (5 of whom had had prophylactic tocilizumab), while steroids were used for the treatment of persistent grade 2 CRS in two patients. Five NHL subjects developed grade 1–2 (n = 3) or grade 3–4 (n = 2) ICANS at a median of 7 days (range, 4–12). All events resolved with corticosteroids, and there were no instances of brain edema. All NHL patients had grade 3–4 neutropenia. Recurrent neutropenia after day 30 was observed in 6 NHL subjects. Anemia was observed in all patients, (grade 3–4, n = 15), and thrombocytopenia in 21 patients (grade 3–4, n = 13). The most common non–hematologic toxicity was grade 1–2 fatigue, (n = 14). There were no grade 3–4 non-hematologic toxicities other than CRS or ICANS.
Five patients died in the follow-up period. Four patients died after relapse or progression of NHL. One patient died 8 days after CAR T cell infusion after experiencing severe CRS (Supplementary Table 6).
In NHL patients, prophylactic tocilizumab resulted in higher plasma concentrations of IL-6 on days 2 and 6 after CAR-T cell infusion, although the difference compared to patients treated without prophylaxis did not reach statistical significance (Supplementary Fig. 5).
Analysis of infused CD19 CAR T cell products show memory CD8+ TCF7+ cells were associated with CR and a transitional memory-like phenotype was associated with the absence of severe CRS
To identify correlates of clinical outcomes, the lymphoma cohort was divided into two groups. Responders (R; n = 12) included patients who had achieved CR and non-responders (NR; n = 5) included participants with PR, progressive or stable disease. Comparison of the Area Under the Curve of percentages of CAR+ T cells in patients at days 6, 14, and 21 showed that responders had a significantly higher percentage (p = 0.0120) of CAR19 T cells (Fig. 5A).
We performed unsupervised clustering analysis of cell surface phenotypes to identify a unique population of CD8+ T cells in the CAR19 cells compartment associated with response. Out of 18 clusters evaluated, only cluster 4 significantly positively correlated with percentages of CAR19 T cells (rho = 0.7187, p = 0.0050; Fig. 5B). Phenotypic characterization of cluster 4 (Fig. 6A) showed that this cluster exhibited upregulation of memory markers CD45RO, CD27 and CCR7, and TCF7, a transcription factor that has been shown to be expressed by long-lived T cells23, indicating that these cells share a phenotype of memory T cell stem24,25. Additionally, these cells showed low expression of CD127, 41BB, and did not express Ki67.
Next, surrogate markers of CRS were evaluated. Patients were divided into two groups: CRS+ (n = 6, with grade 2 or higher CRS), and CRS− (n = 11, with grade 1 or no CRS). As Interleukin 6 (IL-6) plays a central role in acute inflammation26, IL-6 plasma levels were evaluated on day 6. As expected, patients with CRS showed significantly elevated levels of IL-6 (Fig. 5C). There was no correlation of CD8 T cell clusters with day 6 IL-6. However, cluster 9 in the CD4+ CAR19 T cell compartment was significantly lower (p = 0.0245) in the CRS+ group (Fig. 5D). This cluster (Fig. 6B) showed upregulation of memory markers CD45RO and CCR7, TCF7, the marker of T cell stemness, CD127, the IL-7 receptor also highly expressed by memory T cell stem cells and other long-lived cells and the proliferation marker Ki67. Therefore, cluster 9 CD4+ cells are present at higher frequencies in patients with minimal or no CRS.
We describe successful place-of-care manufacturing of CAR19 T cells in two disparate clinical sites. Severe toxicity occurred in association with high disease volume, reflecting the advanced disease status of patients treated here19,20,27. Response rates were at least comparable to published experience. The role of prophylactic tocilizumab in this setting is under investigation.
Place-of-care offers several advantages over centralized manufacturing, including reduced vein-to-vein time due to lack of transport to a centralized facility and the ability to infuse fresh and not necessarily cryopreserved products. Simplified logistics increase flexibility to make decisions based upon patient disease status, for example, split-dosing in the instance of a high tumor burden. Interestingly, fresh cells provided faster tumor control in animals, as compared to cryopreserved cells.
We used the GMP-compliant CliniMACS Prodigy® closed-cell manufacturing system with associated materials and reagents. The device, materials, and reagents used between the two clinical sites were identical. Despite the distinct nature of the apheresis product (pediatric vs. adult), transduction efficiency and cellular composition were consistent between the two sites. Moreover, the median apheresis to infusion time was 13 days, a shorter interval than that reported by others20. This time may be further reduced to 8 days22. As a result of the shorter apheresis to infusion time, most enrolled patients received CAR19.
Patients that achieved CR had a higher frequency of long-lived memory CD8+ TCF7+ cells. Interestingly, others have associated this cell subtype with positive outcomes after CAR T and other cancer treatments, such as melanoma28,29. We, therefore, identified product cell subsets correlated to tumor control and CRS, and enriching for these subpopulations may improve clinical outcomes.
CAR19 was highly effective in inducing disease response. Most of our ALL patients became MRD-negative. However, relapse was the main cause of treatment failure. The targeting of multiple antigens may be necessary to address the issue of antigen escape30,31. Post CAR T cell allogeneic transplant is also under investigation. Our approach increases the likelihood of receiving CAR therapy, but patients that would not be eligible due to disease progression while waiting for product manufacture may also be more likely to suffer toxicity or infections. However, brain edema has not been reported in patients treated with 4-1-BB CAR-T in pediatric ALL, and it is unclear if prophylactic tocilizumab was a contributing factor in severe ICANS in that subgroup. Others have used pre-emptive or prophylactic tocilizumab without unexpected side effects32,33. Toxicity mitigation strategies now under investigation for patients with large leukemia volume include CAR19 split dosing and use of 0.5 × 106 CAR19/kg for NHL patients with bulky disease. The ELIANA study that led to the FDA approval of Tisagenlecleucel to treat pediatric ALL reported that 4.4% (n = 3) of patients had fatal infections, with a 12-month relapse-free survival of 59% (95% CI 41–73)12. In a recent registry retrospective analysis, 23% of ALL patients treated with Tisagenlecleucel developed clinically significant infections34.
Lymphoma responses were sustained. We observed a relapse-free survival (RFS) of 81.2% in the NHL cohort, which should be compared to larger series of patients treated with anti-CD19 CAR T cells that reported one-year RFS of 65% and 79%35,36.
Our studies show that place-of-care manufacture of CAR-T cells results in a consistent cell product and effective clinical outcomes, despite being manufactured in two disparate clinical centers. We, therefore, conclude that place-of-care manufacture of CAR-T cells is a valid paradigm for the manufacture and distribution of CAR-T cells among multiple clinical sites, particularly for patients with rapidly progressive, symptomatic lymphoma and ALL12,19,20.
Design of the chimeric antigen receptor targeting CD19
Lentiviral vectors encoding CAR19 or CAR19.8 were manufactured, and human primary T cells were transduced with each lentiviral vector. CAR expression was measured on the surface of transduced T cells by flow cytometry (Fig. 1B). Cells were stained with CD19-Fc reagent, followed by anti-Fc F(ab)′2-AF 647 conjugate. Non-transduced T cells maintained under the same conditions as CAR-transduced cells were used as a negative control. Robust expression of both CAR19 and CAR19.8 constructs was reproducibly achieved in three separate transduction experiments using different T cell donors (Fig. 1B, one representative donor is shown).
Flow cytometric analysis of CAR surface expression
For cell staining, half a million CAR T-transduced cells were harvested from culture, washed two times in cold AutoMACS buffer supplemented with 0.5% bovine serum albumin (Miltenyi Biotec), and CAR surface expression detected by staining with CD19-Fc peptide (R&D, Minneapolis, MN) followed by anti-Fc-AF647 conjugate (Jackson Immuno Research, West Grove, PA). Non-transduced cells were used as negative controls. Dead cells in all studies were excluded by 7AAD staining (BD Biosciences, San Jose, CA, USA). Cells were washed twice and resuspended in 200 μL Staining Buffer before quantitative analysis by flow cytometry. Flow cytometric analysis was performed on a MACSQuant®10 Analyzer (Miltenyi Biotec), and data plots were generated using FlowJo software (Ashland, OR, USA).
Effector cell function was tested using standard 51Cr release assays as previously described37 and used targets expressing CD19+ cancer cell lines Raji (NHL), Reh (ALL), or with CD19− control lines K562 or 293T (all cell lines obtained from ATCC). In the most recent experiments, autologous T-cell blasts were added as a negative control.
Effector function of CAR T cells was evaluated based on the production of IFN-γ, TNF-α, and IL-2 after co-culture with Raji cells by ELISA (10:1 E:T) assays as described below. Supernatants were tested for IFN-γ by ELISA using solid-phase bound anti-IFN-γ, anti-TNF-α, and anti-IL-2 capture antibody (1 μg/mL) and detection by the biotinylated anti-IFN-γ, anti-TNF-α, and anti-IL-2 detection antibody (0.5 μg/mL; both BD Biosciences). The reaction product was visualized by a peroxidase/streptavidin conjugate (1:10,000) and ABTS (Roche Diagnostics).
This study was carried out in compliance with the applicable laws, regulations, and guidelines of the National Institutes of Health (NIH) and with the approval of Covance Preclinical Oncology (formerly MI Bioresearch) Animal Care and Use Committee. The function of CD19-targeting CAR T cells was assessed in vivo. Six to eight-week-old female NOD.Cg-PrkdcscidIl2rgtm1Wjl/SzJ (NSG) mice, 6 per group, were injected i.v. with Raji-luc tumor cells at 5 × 105 Raji/mouse cells on day 0. Tumor burden was determined by in vivo imaging system (IVIS) bioluminescent imaging on day 4, mice were then randomized to groups with equal mean tumor burden, and 5.0 × 106 fresh or frozen CAR T+ cells/mouse (normalized for transduction efficiency) were administered on study day 7. Tumor regression was determined by bioluminescent imaging on days 11, 13, 21, and 28 using a Xenogen IVIS-200 instrument (Perkin Elmer, Shelton, Connecticut). Images were analyzed using Living Image, version 4.1, software (Perkin Elmer), and the bioluminescent signal flux for each mouse was expressed as average radiance (photons per second per cm2 per steradian). To test for possible outliers, mean radiance tumor burden values per animal across time points in each group were compared (n = 5 animals/group). In group CAR19 frozen high dose, mean radiance for one animal was determined to be a significant outlier using Grubbs’ test, with significance level P < 0.05 (two-sided), using the GraphPad platform (https://www.graphpad.com/quickcalcs/Grubbs1.cfm). Subsequently, the outlier animal was excluded from the graph and the statistical analysis.
Manufacturing CAR T cells using the Automated CliniMACS Prodigy® platform
Pre-clinical studies were performed at the Research and Development Laboratory at Lentigen. CAR T cells were manufactured in the CliniMACS Prodigy® (Miltenyi Biotec) device as previously described37,38 at either the Dmitriy Rogachev Center, Moscow, or University Hospitals Seidman Cancer Center, Cleveland. The CliniMACS Prodigy® (Miltenyi Biotec, Bergisch Gladbach, Germany) device was programmed using the TCT software program. TS520 tubing set was used for manufacture (Miltenyi Biotec, Bergisch Gladbach, Germany). Clinical-grade reagents used to manufacture the CAR-T cells included: CliniMACS Buffer, TexMACS Media, CliniMACS CD4 reagent, CliniMACS CD8 reagent, TransAct, and the cytokines IL-7 and IL-15 (Miltenyi Biotec, Bergisch Gladbach, Germany). The reagents were used according to the manufacturer’s instructions. One 25 μg vial each of IL-7 and IL-15 was added per 2 L bag of media. A 25% stock solution of Human Serum Albumin (HSA) was used to supplement the CliniMACS Buffer to a concentration of 0.5%. Human AB serum was used to supplement the TexMACS Media to a concentration of 3% and was from Innovative Research (Novi, MI, USA). TexMACS media was supplemented with Human AB serum for 6 days of the cell culture and then replaced with media without Human AB serum for the duration of the culture. The CliniMACS Prodigy was loaded with ~1 × 108 CD3 cells and the cells expanded with anti-CD3/CD28 co-stimulation and IL-7/IL-15 supplementation. Following the manufacture protocol, CAR-T cells were harvested initially on day 12 of culture, and after a subsequent protocol modification, harvest on day 8 of culture was permitted.
Analysis of CD19 CAR T cell infusion products
Immune-phenotypic characterization of CAR-T products was performed by Flow Cytometry, using the BD FACSymphonyTM Flow Cytometer. Antibodies used in the panels tested included: Viability stain dye (Invitrogen), CD3 BV570 (Biolegend), CD4 BUV563 (BD), CD8 BUV496 (BD), CD19CAR FITC (Acro Biosystem), CD45RO BUV395 (BD), CD27 BV421 (BD), CCR7 BUV805 (BD), 41BB BV650 (BD), TCF7 PE (BD) and Ki67 PE-Cy5 (ThermoFisher). Flow Cytometry data were analyzed by FlowJo v. 10.7. The gating strategy consisted of a set of steps starting from lymphocytes, based on SSC-A and FSC-A; single cells, based on FCS-H and FSC-A; and live cells, based on MFI for Viability dye. Consecutively specific gating was done in each population of interest e.g. CD4+ T cells, CD8+ T cells, etc. Lastly, populations of interest were concatenated and exported for unbiased clustering analysis, which was done using the Rphenograph package (https://github.com/jacoblevine/PhenoGraph). Projection of the density of cells expressing markers evaluated (above mentioned) was visualized using a non-linear dimensionality reduction technique, Uniform Manifold Approximation, and Projection (UMAP). All correlations were done using Spearman correlation. All statistical comparisons were done using the Mann–Whitney U test. Statistical analysis was performed using Graph Pad Prism version 8.
Clinical trial design and toxicity monitoring
Two separate clinical trials are discussed here. The trials were registered at clinicaltrials.gov under NCT03467256 (ALL) and NCT03434769 (NHL). The pediatric ALL study was approved by the Institutional Review Board of the Dmitriy Rogachev National Medical Center of pediatric hematology and the adult Non-Hodgkin Lymphoma Study was approved by the Institutional Review Board of University Hospitals Cleveland Medical Center. All human subject research was conducted according to the criteria set by the Declaration of Helsinki, and all participants or their legal guardians provided written informed consent. Thirty-one pediatric patients with ALL were enrolled between February 2018 and May 2019. Twenty-three lymphoma patients were enrolled between July 2018 and March 2020.
ALL patients were treated at four dose levels (0.1 × 106, 0.5 × 106, 1 × 106 and 3 × 106 CAR19 cells/kg) (Supplementary Fig. 3A). NHL patients received 0.5 × 106 (n = 4), 1 × 106 (n = 16), or 2 × 106 (n = 3) CAR19 cells/kg (Supplementary Fig. 3B).
Dose-limiting toxicity (DLT) in the ALL trial was defined as grade 4 and 5 SAE, excluding sepsis/septic shock in patients with bone marrow aplasia. Cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS) were graded and managed as previously described39. In the NHL study, DLT has defined as grade ≥3 nonhematologic toxicities and grade ≥4 hematologic toxicities of more than 21-day duration, graded per NCI Common Terminology Criteria for Adverse Events (CTCAE) version 5.0 and grade. Exceptions to the DLT definition included laboratory abnormalities without symptoms and resolved within 7 days, grade 2 or lower CRS, grade 3 CRS that improved to grade 2 within 3 days, and grade 3 or lower ICANS that improved to grade 1 within 3 days.
Possible neurotoxic effects were evaluated daily during an inpatient stay and in all outpatient visits. At baseline and then at approximately 14 and 21 days post-infusion, the caregiver of the patient or the adult patient also completed a neuro-symptom checklist40.
Eligibility criteria are summarized at clinicaltrials.gov and the full list is available in the study protocols (provided as Supplementary Notes 1, 2 within the Supplementary Information file). Patients were eligible if their disease had recurred after standard upfront therapy and at least one (ALL) or two salvage therapies (NHL).
ALL patients had a baseline bone marrow aspiration and lumbar puncture performed within 14 days before the lymphodepletion preparative regimen. Bone marrow biopsy and lumbar puncture were performed 28 ± 4 days from cell infusion, and after 2, 3, 6, 9, and 12 months. Complete remission (CR) was defined by morphologic assessment of the bone marrow (<5% blasts) with no extramedullary disease. Measurable residual disease (MRD) was assessed by multiparametric flow cytometry with a sensitivity of 10−4. NHL disease status and the response were assessed by PET scans performed prior to, and at 1, 2, 6, and 12 months after CAR19.
ALL patients received fludarabine 30 mg/m2 daily for 4 days and cyclophosphamide 750 mg/m2, while NHL patients received fludarabine 25 mg/m2 daily for 3 days and cyclophosphamide 60 mg/kg. The choice of a higher dose of cyclophosphamide was used based on original studies by Turtle and colleagues15. Given that patients were not allowed to receive bridging chemotherapy due to the rapid manufacture time, a larger dose was considered also necessary for disease control.
Univariate analyses of patient characteristics used Fisher’s exact test for categorical variables and Wilcoxon signed-rank test for continuous variables. Overall survival (OS), progression-free survival (PFS), and duration of response estimates were done using the Kaplan–Meier method.
For studies of the infused cell product, unbiased clustering analysis was done using the Rphenograph package (https://github.com/jacoblevine/PhenoGraph). Projection of the density of cells expressing specific markers was visualized using a non-linear dimensionality reduction technique: uniform manifold approximation and projection (UMAP). All correlations of cell phenotype were done using Spearman correlation and statistical comparisons were done using Mann–Whitney U test. Statistical analysis was performed using Graph Pad Prism version 8 and R and its packages (http://cran.r-project.org).
Further information on research design is available in the Nature Research Reporting Summary linked to this article.
Respective study protocols of the two clinical trials are available as Supplementary Notes 1-2 in the Supplementary Information File. Any requests for additional data, materials, or clinical data will be reviewed by each of the Institutional Review Boards and will require a Material Transfer Agreement in place. Patient-related data not included in the paper were generated as part of a clinical trial and are subject to patient confidentiality. All data shared will be de-identified. Any requests for further data should be addressed to the corresponding authors (email@example.com or firstname.lastname@example.org). The remaining data are available within the Article, Supplementary Information or Source Data File. Source data are provided with this paper.
Hunger, S. P. & Mullighan, C. G. Acute lymphoblastic leukemia in children. N. Engl. J. Med. 373, 1541–1552 (2015).
Ko, R. H. et al. Outcome of patients treated for relapsed or refractory acute lymphoblastic leukemia: a Therapeutic Advances in Childhood Leukemia Consortium study. J. Clin. Oncol. 28, 648–654 (2010).
Pui, C. H., Carroll, W. L., Meshinchi, S. & Arceci, R. J. Biology, risk stratification, and therapy of pediatric acute leukemias: an update. J. Clin. Oncol. 29, 551–565 (2011).
Schrappe, M. et al. Outcomes after induction failure in childhood acute lymphoblastic leukemia. N. Engl. J. Med. 366, 1371–1381 (2012).
Sehn, L. H. & Gascoyne, R. D. Diffuse large B-cell lymphoma: optimizing outcome in the context of clinical and biologic heterogeneity. Blood 125, 22–32 (2015).
Dunleavy, K. & Wilson, W. H. Primary mediastinal B-cell lymphoma and mediastinal gray zone lymphoma: do they require a unique therapeutic approach? Blood 125, 33–39 (2015).
Casulo, C., Burack, W. R. & Friedberg, J. W. Transformed follicular non-Hodgkin lymphoma. Blood 125, 40–47 (2015).
Crump, M. et al. Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study. Blood 130, 1800–1808 (2017).
Stamenkovic, I. & Seed, B. CD19, the earliest differentiation antigen of the B cell lineage, bears three extracellular immunoglobulin-like domains and an Epstein-Barr virus-related cytoplasmic tail. J. Exp. Med. 168, 1205–1210 (1988).
Scheuermann, R. H. & Racila, E. CD19 antigen in leukemia and lymphoma diagnosis and immunotherapy. Leuk. Lymphoma 18, 385–397 (1995).
Topp, M. S. et al. Phase II trial of the anti-CD19 bispecific T cell-engager blinatumomab shows hematologic and molecular remissions in patients with relapsed or refractory B-precursor acute lymphoblastic leukemia. J. Clin. Oncol. 32, 4134–4140 (2014).
Maude, S. L. Tisagenlecleucel in pediatric patients with acute lymphoblastic leukemia. Clin. Adv. Hematol. Oncol. 16, 664–666 (2018).
Kochenderfer, J. N. et al. B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells. Blood 119, 2709–2720 (2012).
Kochenderfer, J. N. et al. Chemotherapy-refractory diffuse large B-cell lymphoma and indolent B-cell malignancies can be effectively treated with autologous T cells expressing an anti-CD19 chimeric antigen receptor. J. Clin. Oncol. 33, 540–549 (2015).
Turtle, C. J. et al. Immunotherapy of non-Hodgkin’s lymphoma with a defined ratio of CD8+ and CD4+ CD19-specific chimeric antigen receptor-modified T cells. Sci. Transl. Med. 8, 355ra116 (2016).
Kochenderfer, J. N. et al. Long-duration complete remissions of diffuse large B cell lymphoma after anti-CD19 chimeric antigen receptor T cell therapy. Mol. Ther. 25, 2245–2253 (2017).
Holzinger, A., Barden, M. & Abken, H. The growing world of CAR T cell trials: a systematic review. Cancer Immunol., immunotherapy 65, 1433–1450 (2016).
Majzner, R. G. & Mackall, C. L. Clinical lessons learned from the first leg of the CAR T cell journey. Nat. Med. 25, 1341–1355 (2019).
Schuster, S. J. et al. Chimeric antigen receptor T cells in refractory B-cell lymphomas. N. Engl. J. Med. 377, 2545–2554 (2017).
Neelapu, S. S. et al. Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma. N. Engl. J. Med. 377, 2531–2544 (2017).
Schneider, D. et al. A unique human immunoglobulin heavy chain variable domain-only CD33 CAR for the treatment of acute myeloid leukemia. Front. Oncol. 8, 539 (2018).
Schneider, D. et al. Transmembrane and linker domain amino acid composition alters chimeric antigen receptor (CAR) membrane residence and may conceal detection of novel functional CAR formats. In 34th Annual Meeting & Pre-Conference Programs of the Society for Immunotherapy of Cancer (SITC 2019): Part 1, Vol. 7, 20 (Society for Immunotherapy of Cancer, 2019).
Gattinoni, L., Speiser, D. E., Lichterfeld, M. & Bonini, C. T memory stem cells in health and disease. Nat. Med. 23, 18–27 (2017).
Deng, Q. et al. Characteristics of anti-CD19 CAR T cell infusion products associated with efficacy and toxicity in patients with large B cell lymphomas. Nat. Med. 26, 1878–1887 (2020).
Krishna, S. et al. Stem-like CD8 T cells mediate response of adoptive cell immunotherapy against human cancer. Science 370, 1328–1334 (2020).
Wolf, J., Rose-John, S. & Garbers, C. Interleukin-6 and its receptors: a highly regulated and dynamic system. Cytokine 70, 11–20 (2014).
Maude, S. L. et al. Chimeric antigen receptor T cells for sustained remissions in leukemia. N. Engl. J. Med. 371, 1507–1517 (2014).
Deng, Q. et al. Characteristics of anti-CD19 CAR T cell infusion products associated with efficacy and toxicity in patients with large B cell lymphomas. Nat. Med. 26, 1878–1887 (2020).
Sade-Feldman, M. et al. Defining T cell states associated with response to checkpoint immunotherapy in melanoma. Cell 175, 998–1013 e1020 (2018).
Shah, N. N. et al. Bispecific anti-CD20, anti-CD19 CAR T cells for relapsed B cell malignancies: a phase 1 dose escalation and expansion trial. Nat. Med. 26, 1569–1575 (2020).
Schneider, D. et al. Trispecific CD19-CD20-CD22–targeting duoCAR-T cells eliminate antigen-heterogeneous B cell tumors in preclinical models. Sci. Transl. Med. 13, eabc6401 (2021).
Gardner, R. A. et al. Preemptive mitigation of CD19 CAR T-cell cytokine release syndrome without attenuation of antileukemic efficacy. Blood 134, 2149–2158 (2019).
Kadauke, S. et al. Risk-adapted preemptive tocilizumab to prevent severe cytokine release syndrome after CTL019 for pediatric B-cell acute lymphoblastic leukemia: a Prospective Clinical Trial. J. Clin. Oncol. 134, 920–930 (2021).
Pasquini, M. C. et al. Real-world evidence of tisagenlecleucel for pediatric acute lymphoblastic leukemia and non-Hodgkin lymphoma. Blood Adv. 4, 5414–5424 (2020).
Abramson, J. S. et al. Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study. Lancet 396, 839–852 (2020).
Schuster, S. J. et al. Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma. N. Engl. J. Med. 380, 45–56 (2019).
Zhu, F. et al. Closed-system manufacturing of CD19 and dual-targeted CD20/19 chimeric antigen receptor T cells using the CliniMACS Prodigy device at an academic medical center. Cytotherapy 20, 394–406 (2018).
Jackson, Z. et al. Automated manufacture of autologous CD19 CAR-T cells for treatment of non-Hodgkin lymphoma. Front. Immunol. 11, 1941 (2020).
Lee, D. W. et al. Current concepts in the diagnosis and management of cytokine release syndrome. Blood 124, 188–195 (2014).
Weintraub, S. et al. Cognition assessment using the NIH Toolbox. Neurology 80, S54–S64 (2013).
We thank K. Schonely and M. Artlip for developing, validating, and performing the qPCR assays used in the study. We thank S. Siddiqui for his assistance in writing the paper. Studies were funded by Lentigen, a MiltenyiBiotec Company. Clinical and correlative studies at Dmitriy Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology, Moscow, Russian Federation were funded by the Science for Children foundation and PodariZhizn. A.S. was supported by Russian Scientific Foundation project No. 17-74-30019. Studies at University Hospitals Seidman Cancer Center, Cleveland, OH were funded by institutional funds. The sponsors did not have any role in the trial conduct, data collection, and results reporting.
D.S., Y.X., D.W., A.K., W.K., A.W. and M.K. are employees of Lentigen, a MiltenyiBiotec Company. The remaining authors declare no competing interests.
Peer review information
Nature Communications thanks Michael Jain, Monica Mead, Jae Park, Qian Wu and the other, anonymous, reviewer(s) for their contribution to the peer review of this work.
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
About this article
Cite this article
Maschan, M., Caimi, P.F., Reese-Koc, J. et al. Multiple site place-of-care manufactured anti-CD19 CAR-T cells induce high remission rates in B-cell malignancy patients. Nat Commun 12, 7200 (2021). https://doi.org/10.1038/s41467-021-27312-6
This article is cited by
Decentralized manufacturing of anti CD19 CAR-T cells using CliniMACS Prodigy®: real-world experience and cost analysis in India
Bone Marrow Transplantation (2023)
Suppression of cytokine release syndrome during CAR-T-cell therapy via a subcutaneously injected interleukin-6-adsorbing hydrogel
Nature Biomedical Engineering (2023)
Nature Biotechnology (2023)
Long-term response to autologous anti-CD19 chimeric antigen receptor T cells in relapsed or refractory B cell acute lymphoblastic leukemia: a systematic review and meta-analysis
Cancer Gene Therapy (2023)